Lung parenchyma is the most common site of metastatic disease
other than the liver for tumors that drain into the portal system
(Table 1). Of patients dying from metastatic disease to the lung,
20% to 25% may have no other evidence of metastases [1,2]. In
some instances, such as osteogenic and soft-tissue sarcomas in
adults, isolated pulmonary metastases represent the first recurrence
in 50% of patients [3,4].
Isolated case reports, followed by larger, more selected series,
have defined a set of criteria for patient suitability for surgical
resection of pulmonary metastases. Initially, patients with a
single metastasis and long tumor-free intervals were selected.
However, over time, the survival advantage of performing resections
in patients with unilateral multiple disease, bilateral multiple
disease, and even multiorgan disease, including the lung and liver,
have further extended the indications.
Frequently, chemotherapy and radiation therapy are used for palliation,
but only surgical extirpation, with or without multimodality therapy,
can realize a cure in selected instances. Combined studies confirm
an overall 5-year survival of 30% with low operative morbidity
In patients with a history of malignancy, the presence of new
pulmonary lesions should suggest the possibility of metastatic
disease. Once new nodule(s) are identified, a short, but important
list of criteria must be considered prior to resection. Even though
surgical metastatectomy has been performed for over 40 years,
the criteria have not changed significantly . Although there
are exceptions to every rule in medicine, the following standards
should be considered:
- The primary tumor site should be free of disease.
- Metastases should be confined to the lungs.
- The number of nodules should be "reasonable" (depending
on the histology).
- Chemotherapy is not curative.
- The patient can tolerate surgical therapy.
Standards, such as a specific doubling time, histology of the
primary tumor, and length of disease-free interval are variable.
However, these factors also should be considered in evaluating
resectability in the individual patient.
Attempts to rule out a lung primary carcinoma should be made,
as this would impact on the type and extent of operation recommended.
A history and physical examination, with evaluation of symptoms
and smoking status (and thus risk), are essential. Characteristics
of the nodule(s) on the chest radiograph and CT scan should suggest
either a primary or a secondary carcinoma. Most patients with
metastatic lung lesions are asymptomatic; however, this may also
be true for those with early-stage lung cancer. The presence of
hemoptysis, cough, or pain would more likely be associated with
a primary malignancy than a metastasis.
McCormack and Martini of Memorial Sloan-Kettering Cancer Center
found that a solitary pulmonary lesion was most likely a metastasis
if the primary was a sarcoma or melanoma, and a new primary if
the other malignancy was in the head and neck or breast; if the
previous lesion was of gastrointestinal or genitourinary origin,
however, a secondary or primary carcinoma was equally likely .
Although the majority of metastatic nodules are identified on
initial or follow-up chest x-rays, a chest CT scan is required
to obtain a more sensitive assessment of the number and characteristics
of the nodules. A chest x-ray may detect a 1-cm nodule, but a
CT scan may identify nodules 3 mm in size. With this increased
definition of nodules, specificity decreases, such that more benign
lesions, such as intraparenchymal lymph nodes and granulomas,
are revealed as possible metastatic abnormalities.
In a recent review of 144 patients undergoing resection of lung
metastases from colorectal carcinoma, the CT report differed from
pathologic findings in 30 (42%) of 72 patients. Among patients
with one or two radiologically imaged lesions, 12 patients had
fewer cancers (some lesions were benign) identified at surgery
and 18 patients had a higher number of malignant lesions; this
translated into an error rate of 28% . Despite these minor
limitations, CT scanning of the chest is the most sensitive noninvasive
test for preoperative assessment. In the majority of situations,
preoperative diagnosis is unnecessary, but it may be obtained,
if desired, by needle or transbronchial biopsy.
Other Imaging Modalities
Positron emission tomography (PET) is an emerging technology that
shows metastatic lesions as abnormal metabolizers of glucose,
compared to surrounding normal tissues. Current PET scans can
identify malignant nodules > 5 mm in size. Although this modality
has demonstrated excellent accuracy for diagnosing metastatic
melanoma, its sensitivity and specificity has not been confirmed,
particularly for other histologies . We anticipate that, in
the future, PET may provide a more definitive examination and
possibly supplant the CT scan.
Magnetic resonance imaging offers no advantage over CT for the
routine evaluation of metastatic pulmonary nodules.
The evaluation of a patient for resection of pulmonary metastases
is similar to standard prethoracotomy assessments. These procedures
are performed under general anesthesia, and therefore, the patient
must have adequate cardiopulmonary status. Resection of pulmonary
metastases usually does not necessitate a lobectomy and even less
frequently requires a pneumonectomy; therefore, more borderline
pulmonary function results may be acceptable. Clearly, the location
and number of lesions is critical in planning the type of resection
required. Postoperatively, the patient should have no less than
a FEV1 (forced expiratory volume in 1 second) of 800 to 1000 cc;
with a preoperative DCO (diffusing capacity) > 50%; MMV (a
maximum voluntary ventilation) > 50%; and a PCO2 < 45.
Control of the primary site and the absence of further metastatic
disease are confirmed by blood chemistry, brain MRI, bone scan,
and CT or MRI of the primary site. For the majority of metastases,
confirmatory tissue diagnosis of the lesion is unnecessary prior
Type of Incision
The type of incision depends on the location and extent of the
lesions. If the lesions are peripheral and bilateral, a median
sternotomy may be appropriate. This has the advantages of less
postoperative pain, more rapid early recovery of pulmonary function,
and better identification of bilaterality that may not have been
detected in the preoperative evaluation . Of patients demonstrating
unilateral metastases on CT scan, 45% have bilateral disease at
A posterior lateral thoracotomy, particularly on the left, may
be preferable for a lower lobectomy or posterior wedge resection
and for adequate resection of the diaphragm that is contiguous
with the metastasis. In these instances, with information known
from the preoperative CT scan concerning bilaterality and diaphragmatic
extension, staged thoracotomies would be more appropriate. Also,
if a previous median sternotomy has been performed, repeated access
may be more difficult, and thoracotomies may be preferred for
further resections. The transverse or clamshell incision should
also be considered for patients who have bilateral disease, especially
in the lower lobes [11,12].
Video-Assisted Thoracoscopy Surgery
Video-assisted thoracoscopy surgery (VATS) is a newer surgical
approach that may have been overutilized recently. Most surgeons
are concerned that the video-assisted technique does not allow
for manual palpation of the lungs in order to identify small (<
5 mm) lesions seen on CT scan. As described above, a retrospective
review demonstrated a 28% error rate of CT scans, compared with
pathologic results . This suggests that VATS might have missed
these other lesions that were identified at the time of open thoracotomy.
The results of an ongoing randomized trial examining the efficacy
of VATS will hopefully settle this issue.
The claim that patients undergoing VATS-wedge resections have
reduced morbidity, cost, and hospital stay has yet to be verified
with certainty.13 Moreover, the incidence of local recurrences
at the resection margins, in the pleural space, and in port sites
may be higher after thoracoscopic resection of metastatic disease.
It is extremely important not to spill tumor contents into the
pleural space. This can occur when the stapling device is used,
and may happen without the surgeon's knowledge because of a contaminated
resection margin. Once a pleural spill occurs, patients may progress
to pleural metastatic disease, which usually is not curatively
At present, we recommend an open resection, preferably with simultaneous
bilateral dissections, in clinically qualified patients. Video-assisted
thoracoscopy resection is not advocated as conventional therapy,
but may be reserved for the occasional patient who has limited
pulmonary function and a single metastasis with a long disease-free
The goal of resection is to remove all identified or palpated
disease with the minimal volume of normal surrounding parenchyma.
This is usually achieved by a wedge resection, Perelman resection
(precision excision with either cautery or laser), lobectomy,
or pneumonectomy, depending on the location of the nodule. An
adequate resection margin of 0.5 cm is preferred, but unfortunately,
is not always feasible. A cytologic touch preparation of the resected
margin should always be performed if the margin is suspicious
When the primary and metastatic lesions present simultaneously,
surgical treatment of the primary should be done initially. If
a curative resection of the primary can be performed successfully,
metastatectomy should be carried out approximately 4 weeks postoperatively.
If resection of the primary is noncurative, usually there is no
need to resect the pulmonary metastases.
Recently, extensive metastatic disease isolated to the lungs has
been perfused with chemotherapeutic agents in animal and clinical
models [14,15]. The techniques no longer require systemic circulatory
assist and can be performed bilaterally through a mid-line sternotomy
(HI Pass, MD, personal communication, October 1995). Although
presently experimental, the rationality and efficacy of organ
perfusion based on the liver perfusion model warrants further
1. Farrell JT: Pulmonary metastasis: A pathological , clinical
and roentgenologic study based on 78 cases at necropsy. Radiology
2. Temple WJ, Kethcam AS: Surgical management of isolated systemic
metastasis. Semin Oncol 7:468-480, 1980.
3. Giuliano AE, Feig S, Eilber FR: Changing metastatic patterns
of osteosarcoma. Cancer 54:2160-2164, 1984.
4. Potter DA, Glenn J, Kinsella T, et al: Patterns of recurrence
in patients with high-grade soft-tissue sarcomas. J Clin Oncol
5. Ramming KP: Surgery for pulmonary metastases. Surg Clin North
Am 60(4):815-824, 1980.
6. McCormack PM, Martini N: The changing role of surgery for pulmonary
metastases. Ann Thorac Surg 28(2):141-145, 1979.
7. McCormack PM, Ginsberg KB, Bains MS, et al: Accuracy of lung
imaging in metastases with implications for the role of thoracoscopy.
Ann Thorac Surg 56:863-866, 1993.
8. Boni R, Boni RA, Steinert H, et al: Staging of metastatic melanoma
by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose.
Br J Dermatol 132(4):556-562, 1995.
9. Cooper JD, Nelems JM, Pearson FG: Extended indications for
median sternotomy in patients requiring pulmonary resection. Ann
Thorac Surg 26:413-420, 1978.
10. Roth JA, Pass HI, Wesley MN, et al: Comparison of median sternotomy
and thoracotomy for resection of pulmonary metastases in patients
with adult soft tissue sarcomas. Ann Thorac Surg 42:134-138, 1986.
11. Rusch VW: Pulmonary metastatectomy: Current indications (suppl).
Chest 107(6):322S-331S, 1995.
12. Bains MS, Ginsberg RJ, Jones WG, et al: The clamshell incision:
An improved approach to bilateral pulmonary and mediastinal tumor.
Ann Thorac Surg 58(1):30-32, 1994.
13. Dowling RD, Ferson PF, Landreneau RJ: Thoracoscopic resection
of pulmonary metastases. Chest 102:1450-54, 1992.
14. Weksler B, Lenert J, Ng B, et al: Isolated single lung perfusion
with doxorubicin is effective in eradicating soft tissue sarcoma
lung metastases in a rat model. J Thorac Cardiovasc Surg 107:50-54,
15. Johnston MR, Minchen RF, Dawson CA: Lung perfusion with chemotherapy
in patients with unresectable metastatic sarcoma to lung or diffuse
bronchoalveolar carcinoma. J Thorac Cardiovasc Surg 110:368-373,
16. Marcove RC, Mike V, Hajek JV, et al: Osteogenic sarcoma under
the age of 21: A review of 145 operative cases. J Bone Joint Surg
17. Holmes EC: Pulmonary metastases, in Pearson FG, Deslauriers
J, Ginsberg RJ, et al (eds): Thoracic Surgery, p 8331. New York,
Churchill Livingstone, 1995.
18. Telander RL, Pairolero PC, Pritchard DJ, et al: Resection
of pulmonary metastatic osteogenic sarcoma in children. Surgery
19. Giritsky AS, Etcubanas E, Mark JBD: Pulmonary resection in
children with metastatic osteogenic sarcoma. J Thorac Cardiovasc
Surg 75:354-362, 1978.
20. Putnam JB, Roth JA, Wesley MN, et al: Analysis of prognostic
factors in patients undergoing resection of pulmonary metastases
from soft tissue sarcomas. J Thorac Cardiovasc Surg 87:260-268,
21. Goorin AM, Shuster JJ, Baker A, et al: Changing patterns of
pulmonary metastases with adjuvant chemotherapy in patients with
osteosarcoma: Results from the multi-institutional osteosarcoma
study. J Clin Oncol 9:600-605, 1991.
22. Pastorino U, Gasparini M, Tavecchio L, et al: The contribution
of salvage surgery to the management of childhood osteosarcoma.
J Clin Oncol 9:1357-1362, 1991.
23. Eilber FR, Eckardt J: Adjuvant therapy for osteosarcoma: A
randomized prospective trial. Proc Am Soc Clin Oncol 4:144, 1985.
24. Link M, Goorin A, Miser A, et al: The role of adjuvant chemotherapy
in the treatment of osteosarcoma of the extremity: Preliminary
results of the multi-institutional osteosarcoma study. Proc Am
Soc Clin Oncol 4:237, 1985.
25. Martini N, Huvos AG, Mike V, et al: Multiple pulmonary resections
in the treatment of osteogenic sarcoma. Ann Thorac Surg 12:271-280,
26. Roth JA, Putnam JB, Wesley MN, et al: Differing determinants
of prognosis following resection of pulmonary metastases from
osteogenic and soft tissue sarcoma patients. Cancer 55:1361-1366,
27. Creagan ET, Fleming TR, Edmonson JH, et al: Pulmonary resection
for metastatic non-osteogenic sarcoma. Cancer 44:1908-1912, 1979.
28. McCormack PM, Bains MS, Martini N: Surgical management of
pulmonary metastases, in Shiu MH, Brennan MD (eds): Surgical Management
of Soft Tissue Sarcomas, p 263. Philadelphia, Lea & Febiger,
29. van Halteren HK, van Geel AN, Hart AAM, et al: Pulmonary resection
for metastases of colorectal origin. Chest 107:1525-1531, 1995.
30. McAfee MK, Allen MS, Trastek VF, et al: Colorectal lung metastases:
Results of surgical excision. Ann Thorac Surg 53:780-786, 1992.
31. Ramming KP: Surgery for pulmonary metastases. Surg Clin North
Am 60:815-824, 1980.
32. Schlappack OK, Baur M, Steger G, et al: The clinical course
of lung metastases from breast cancer. Klin Wochenschr 66(17):790-795,
33. McDonald ML, Deschamps C, Ilstrup DM, et al: Pulmonary resection
for metastatic breast cancer. Ann Thorac Surg 58(6):1599-1602,
34. Friedel G, Linder A, Toomes H: The significance of prognostic
factors for the resection of pulmonary metastases of breast cancer.
Thorac Cardiovasc Surg 42(2):71-75, 1994.
35. Pogrebniak HW, Haas G, Linehan WM, et al: Renal cell carcinoma:
Resection of solitary and multiple metastases. Ann Thorac Surg
36. Cerfolio RJ, Allen MS, Deschamps C, et al: Pulmonary resection
of metastatic renal cell carcinoma. Ann Thorac Surg 57:339-344,
37. McCormack PM, Bains MS, Beattie EJ, et al: Pulmonary resection
in metastatic carcinoma. Chest 73:163-166, 1978.
38. Mazer JM, Robbins KT, McMurtrey MJ, et al: Resection of pulmonary
metastases from squamous cell carcinoma of the head and neck.
Am J Surg 156:238-242, 1988.
39. Mountain CF, McMurtrey MJ, Hermes KE: Surgery for pulmonary
metastasis: A 20-year experience. Ann Thorac Surg 38:323-330,
40. Mathisen DJ, Flye MW, Peabody S: The role of thoracotomy in
the management of pulmonary metastases from malignant melanoma.
Ann Thorac Surg 27:295-299, 1979.
41. Morrow CE, Vassilopoulos PP, Grage TB: Surgical resection
for metastatic neoplasms of the lung. Cancer 45:2981-2985, 1980.
42. Dahlback O, Hafstrom L, Jonasson PE, et al: Lung resection
for metastatic melanoma. Clin Oncol 6:15-20, 1980.
43. Pogrebniak HW, Stovroff M, Roth JA, et al: Resection of pulmonary
metastases from malignant melanoma: Results of a 16 year experience.
Ann Thorac Surg 46:20-23, 1980.
44. Cahan WG: Excision of melanoma metastases to lung: Problems
in diagnosis and management. Ann Surg 178:703-709, 1973.
45. Gorenstein LA, Putnam JB, Natarajan G, et al: Improved survival
after resection of pulmonary metastases from malignant melanoma.
Ann Thorac Surg 52:204-210, 1991.
46. Tafra L, Dale PS, Wanek LA, et al: Resection and adjuvant
immunotherapy for melanoma metastatic to the lung and thorax.
J Thorac Cardiovasc Surg 110(1):119-128, 1995.
47. Lanza LA, Miser JS, Pass HI, et al: The role of resection
for the treatment of pulmonary metastases from Ewing's sarcoma.
J Thorac Cardiovasc Surg 94:181-187, 1987.
48. Burt M, Karpeh M, Vkoha O, et al: Medical tumors of the chest
wall: Solitary plasmacytoma and Ewing's sarcoma. J Thorac Cardiovasc
Surg 105:89-96, 1993.
49. Callery CD, Holmes EC, Vernon S, et al: Resection of pulmonary
metastases from non-seminomatous testicular tumors: Correlation
of clinical and histological features with treatment outcome.
Cancer 51:1152-1158, 1983.
50. Holmes EC: Pulmonary metastases. Thoracic Surgery, ch 31,
p 831. New York, Churchill Livingstone, 1995.
51. Casson AG, Putnam JB, Natarajan G, et al: Efficacy of pulmonary
metastatectomy for recurrent soft tissue sarcoma. J Surg Oncol
52. Roth JA: Resection of Pulmonary Metastases, in Roth JA, Ruckdeschel
JC, Weisenburger TH (eds): Thoracic Oncology, pp 619-630. Philadelphia,
WB Saunders, 1989.